How Your Heart Ages and What Science Can Do to Slow It Down

Cardiovascular disease is the leading cause of death in older adults, and its prevalence is set to surge dramatically: by 2030, roughly 20% of the global population will be aged 65 or older, and CVD-related deaths are projected to rise by at least 40%. This 2025 narrative review from Italian clinicians synthesizes current knowledge on the biological mechanisms driving age-related cardiovascular decline, with particular attention to molecular pathways amenable to intervention.

At the vascular level, aging triggers a shift in the balance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), and between MMPs and extracellular matrix (ECM) components. Elevated elastolytic MMP activity—particularly MMP-1, -2, -9, -13, and -14—degrades elastin fibers in arterial walls, releasing amorphous elastin degradation products that act as chemotactic signals for leukocytes, smooth muscle cells, and fibroblasts. This triggers a self-perpetuating inflammatory loop. Concurrently, profibrotic mediators such as TGF-β increase collagen and fibronectin deposition, progressively stiffening vessel walls and impairing endothelial function. The clinical consequences include elevated blood pressure, impaired vasodilation, reduced neoangiogenesis, and accelerated atherosclerosis.

The aging heart itself undergoes multiple structural and functional changes. Myocyte loss driven by oxidative stress is compensated by fibroblast proliferation and hypertrophy of surviving cardiomyocytes, reducing contractility and elasticity and causing diastolic dysfunction. Amyloid and calcium deposits accumulate in the myocardium and particularly the aortic valve. Sinoatrial node cell loss, compounded by fibrosis of the conduction system, produces chronotropic disability—reduced resting heart rate and arrhythmia susceptibility. Reduced myocardial calcium utilization, diminished nitric oxide bioavailability, and blunted adrenergic responsiveness further compromise cardiac output and vascular tone.

A unifying mechanism across these changes is inflammaging—a chronic, low-grade pro-inflammatory state characterized by elevated TNF-α, IL-1, IL-6, macrophage activation, and monocyte infiltration in the absence of identifiable infection. The antagonistic pleiotropy theory suggests this inflammatory phenotype was evolutionarily beneficial in youth for combating pathogens, but becomes destructive when sustained into old age. Mitochondrial dysfunction is central: aging mitochondria generate excess reactive oxygen species (ROS), and adaptive responses—including the unfolded protein response (UPRmt), mitochondrial-derived vesicles (MDVs), and mitophagy—become progressively overwhelmed, tipping cells toward apoptosis or necrosis.

For diagnosis and risk stratification, the review highlights circulating biomarkers including BNP (heart failure stress marker), hs-cTnT (myocardial injury), IL-6 (inflammaging marker), and FGF21 (metabolic and mitochondrial stress indicator). These can be combined with non-invasive imaging to characterize early age-related cardiovascular changes. Therapeutically, regular physical exercise and dietary modifications remain foundational. Pharmacological strategies targeting MMP dysregulation (using exogenous MMP inhibitors), inflammatory pathways, oxidative stress (via Nrf2 activation), and RAAS overactivation show promise. The review emphasizes that no single intervention will suffice; a multi-target, personalized approach guided by biomarker profiling and imaging is likely required to meaningfully delay cardiovascular aging.